BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 24927265)

  • 1. The clinical management of chronic myelomonocytic leukemia.
    Padron E; Komrokji R; List AF
    Clin Adv Hematol Oncol; 2014 Mar; 12(3):172-8. PubMed ID: 24927265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
    Padron E; Steensma DP
    Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment].
    Harada Y; Harada H
    Rinsho Ketsueki; 2016 Feb; 57(2):147-55. PubMed ID: 26935632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.
    Parikh SA; Tefferi A
    Am J Hematol; 2012 Jun; 87(6):610-9. PubMed ID: 22615103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Myelomonocytic Leukemia: Focus on Clinical Practice.
    Patnaik MM; Tefferi A
    Mayo Clin Proc; 2016 Feb; 91(2):259-72. PubMed ID: 26848006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.
    Emanuel PD
    Leukemia; 2008 Jul; 22(7):1335-42. PubMed ID: 18548091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytopenia, dysplasia, and monocytosis: a precursor to chronic myelomonocytic leukemia or a distinct subgroup? Case reports and review of literature.
    Singh ZN; Post GR; Kiwan E; Maddox AM
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):293-7. PubMed ID: 21658659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS.
    Xicoy B; Triguero A; Such E; García O; Jiménez MJ; Arnán M; Bernal T; Diaz-Beya M; Valcárcel D; Pedro C; Ramos F; Amigo ML; Collado R; Palomo L; Ardanaz MT; Cedena MT; Grau J; Zamora L; Sanz G
    Leuk Res; 2018 Jul; 70():34-36. PubMed ID: 29775844
    [No Abstract]   [Full Text] [Related]  

  • 9. Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.
    McCullough KB; Patnaik MM
    Curr Hematol Malig Rep; 2015 Sep; 10(3):292-302. PubMed ID: 26122388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management.
    Valent P
    Best Pract Res Clin Haematol; 2020 Jun; 33(2):101137. PubMed ID: 32460976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features.
    Calvo X; Garcia-Gisbert N; Parraga I; Gibert J; Florensa L; Andrade-Campos M; Merchan B; Garcia-Avila S; Montesdeoca S; Fernández-Rodríguez C; Salido M; Puiggros A; Espinet B; Colomo L; Roman-Bravo D; Bellosillo B; Ferrer A; Arenillas L
    Blood Adv; 2020 Oct; 4(20):5285-5296. PubMed ID: 33108455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CMML: Clinical and molecular aspects.
    Itzykson R; Duchmann M; Lucas N; Solary E
    Int J Hematol; 2017 Jun; 105(6):711-719. PubMed ID: 28455647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment.
    Elmariah H; DeZern AE
    Curr Hematol Malig Rep; 2019 Jun; 14(3):154-163. PubMed ID: 31093889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
    Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
    Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Jachiet V; Moulis G; Hadjadj J; Seguier J; Laribi K; Schleinitz N; Vey N; Sacre K; Godeau B; Beyne-Rauzy O; Bouvet R; Broner J; Brun N; Comont T; Gaudin C; Lambotte O; Le Clech L; Peterlin P; Roy-Peaud F; Salvado C; Versini M; Isnard F; Kahn JE; Gobert D; Adès L; Fenaux P; Fain O; Mekinian A
    Haematologica; 2021 May; 106(5):1414-1422. PubMed ID: 33626866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current management of patients with chronic myelomonocytic leukemia.
    Alfonso A; Montalban-Bravo G; Garcia-Manero G
    Curr Opin Oncol; 2017 Jan; 29(1):79-87. PubMed ID: 27849645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment advances for pediatric and adult onset neoplasms with monocytosis.
    McCullough KB; Kuhn AK; Patnaik MM
    Curr Hematol Malig Rep; 2021 Jun; 16(3):256-266. PubMed ID: 33728588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.
    Parikh SA; Tefferi A
    Am J Hematol; 2013 Nov; 88(11):967-74. PubMed ID: 23963888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How I diagnose and treat chronic myelomonocytic leukemia.
    Patnaik MM
    Haematologica; 2022 Jul; 107(7):1503-1517. PubMed ID: 35236051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMML: a biologically distinct myeloproliferative disease.
    Cortes J
    Curr Hematol Rep; 2003 May; 2(3):202-8. PubMed ID: 12901341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.